Cipla schedules analyst meetings in Gurgaon and Mumbai

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Cipla holds analyst meeting at Jefferies India Forum on September 17
  • Company attends Kotak Healthcare Conference on September 18
  • Both engagements are scheduled as in-person events
powered bylight_fuzz_icon
49368554

*this image is generated using AI for illustrative purposes only.

Cipla Limited has announced a schedule of meetings with analysts and institutional investors for mid-September 2026. The company will participate in two in-person events across Gurgaon and Mumbai.

The engagements are scheduled as follows:

Date Conference Name Venue Type
September 17, 2026 Jefferies India Forum Conference Gurgaon In person
September 18, 2026 Kotak Healthcare Conference Mumbai In person

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Rajendra Chopra, Company Secretary, signed the intimation on August 27, 2026.

The schedule is subject to change due to unforeseen circumstances involving the investor or the company.

Historical Stock Returns for Cipla

1 Day5 Days1 Month6 Months1 Year5 Years
+0.25%-1.01%+1.00%+5.59%-9.89%+54.08%

What specific strategic updates or financial guidance is Cipla likely to present at these September 2026 conferences given the current market sentiment?

How might the outcomes of the Jefferies and Kotak conferences influence Cipla's stock valuation in the immediate weeks following the events?

Are there any pending regulatory approvals or pipeline developments that Cipla is expected to highlight to institutional investors during these meetings?

Cipla gets Form 483 with 7 USFDA observations at Pithampur plant

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Cipla received a Form 483 with seven observations from USFDA
  • Inspection was a follow-up visit to Unit IV in Pithampur
  • The facility contributes 30% of the company's total revenue
  • Regulatory outcome may impact US export capabilities
powered bylight_fuzz_icon
48844444

*this image is generated using AI for illustrative purposes only.

Cipla received a Form 483 listing seven observations following a USFDA follow-up inspection at its Pithampur facility. This regulatory development impacts a site contributing 30% of the company's revenue.

Inspection outcome

The USFDA issued the Form 483 after conducting a follow-up visit to Cipla's Unit IV facility in Indore/Pithampur. The document highlights seven specific observations identified during the regulatory review process.

Parameter Details
Facility Unit IV, Indore/Pithampur
Regulatory body USFDA
Inspection type Follow-up visit
Outcome Form 483 issued
Observations 7

USFDA inspections are a standard part of the regulatory oversight process for pharmaceutical manufacturing facilities that supply products to the United States market. The outcome of such inspections can have implications for a company's ability to continue exporting to the US.

Facility significance

The Unit IV facility in Indore/Pithampur is a material manufacturing site for Cipla, accounting for 30% of the company's total revenue. Given the site's substantial contribution to overall business operations, the issuance of a Form 483 is a notable development requiring attention.

Historical Stock Returns for Cipla

1 Day5 Days1 Month6 Months1 Year5 Years
+0.25%-1.01%+1.00%+5.59%-9.89%+54.08%

What specific corrective actions must Cipla implement to address the seven Form 483 observations before the USFDA issues a final warning letter?

How might this regulatory setback impact Cipla's short-term revenue projections given that the Pithampur facility contributes 30% of total earnings?

Will the USFDA impose an Import Alert on products from Unit IV, potentially halting exports to the US market during the remediation period?

More News on Cipla

1 Year Returns:-9.89%